CytoMed Therapeutics Ltd. (GDTC) - Form 20-F Summary
Business Context and Reporting Period
Company: CytoMed Therapeutics Ltd.
Reporting Period: Fiscal year ended December 31, 2025.
Business Overview: A clinical-stage biopharmaceutical company incorporated in Singapore, focused on developing "off-the-shelf" allogeneic cell-based immunotherapies for cancer and degenerative diseases. The company operates primarily through subsidiaries in Malaysia (manufacturing and cord blood banking) and Singapore (R&D and administration).
Key Assets: Proprietary technology platforms licensed from A*STAR (Singapore), a cGMP manufacturing facility in Johor, Malaysia, and a cord blood stem cell banking facility in Malaysia.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 (S$) | 2025 (US$) | 2024 (S$) |
|---|---|---|---|
| Total Revenue | 324,387 | 252,265 | 69,501 |
| Net Loss | (3,996,336) | (3,107,812) | (2,521,861) |
| Accumulated Losses | (18,828,592) | (14,642,345) | (14,848,135) |
| Cash and Bank Balances | 2,095,489 | 1,629,589 | 4,970,367 |
| Total Assets | 7,984,953 | 6,209,622 | 10,067,749 |
| Total Liabilities | 1,131,286 | 879,762 | 1,023,960 |
| Research Expenses | 2,217,495 | 1,724,469 | 1,909,519 |
Note: US$ conversions based on S$1.2859 = US$1.00 (Dec 31, 2025 rate).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 367% to S$324,387 (from S$69,501 in 2024), driven primarily by the expansion of private blood banking services (storage and retrieval) following the acquisition of assets from CellSafe International Sdn Bhd in late 2024.
- Increased Loss: Net loss widened to S$4.00 million (from S$2.52 million in 2024). This was driven by higher research expenses (S$2.22 million vs. S$1.91 million) and increased share-based payment expenses (S$694,200 recognized in 2025).
- Cash Position: Cash and bank balances decreased significantly by 58% to S$2.10 million (from S$4.97 million), reflecting continued operating cash burn of S$3.70 million and capital expenditures.
- Disposal of Associate: The company disposed of its 20% equity interest in Landmark Medical Centre Sdn Bhd (LMC) in December 2025, recognizing a gain of S$294,236.
Guidance, Outlook, and Risks
Outlook & Guidance:
- Product Pipeline: The lead candidate, CTM-N2D (CAR-gamma delta T cells), is in Phase I clinical trials (ANGELICA Trial) at National University Hospital Singapore. Dose level 1 is complete; dose level 2 is ongoing. Patient recruitment is expected to continue in 2026.
- Other Candidates: iPSC-gdNKT and CTM-NK are in pre-clinical development. CTM-GDT is targeting a Phase I trial in Malaysia in late 2026. CTM-MSC is preparing for a Phase I trial for osteoarthritis.
- Capital Needs: The company expects to continue incurring losses for the foreseeable future. It relies on its At-The-Market (ATM) offering program (up to US$4.3 million) and potential future equity/debt financings to fund operations.
Key Risks & Contingencies:
- Going Concern: The company has accumulated losses of S$18.83 million and relies on additional funding to continue operations. Substantial doubt exists regarding its ability to continue as a going concern without further capital.
- Intellectual Property: The company does not own patents; it relies on licenses from A*STAR (via ATPL). Failure to meet commercialization milestones could result in license termination.
- Regulatory & Clinical: Risks include failure of clinical trials, delays in regulatory approvals (HSA, NPRA, FDA), and manufacturing challenges with complex cell therapies.
- Competition: Intense competition from well-funded biopharmaceutical companies developing similar allogeneic CAR-T and cell therapies.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the current S$2.10 million cash balance against the projected burn rate of ~S$3.7 million annually.
- ATM Utilization: Monitor the progress of the ATM offering program (US$4.3 million cap) as a primary near-term funding source.
- Clinical Trial Status: Confirm the safety and efficacy data from the ongoing ANGELICA Trial (CTM-N2D) and the timeline for Phase II expansion.
- License Milestones: Review the specific commercialization milestones required under the A*STAR license agreements to avoid termination.
- Revenue Sustainability: Assess the growth trajectory and profitability of the new cord blood banking segment, which now constitutes the majority of revenue.